- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer Immunotherapy: Sipuleucel-T and Beyond
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 31, Issue 8, Pages 813-828
Publisher
Wiley
Online
2011-07-27
DOI
10.1592/phco.31.8.813
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
- (2010) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Approval of Provenge Seen As First Step for Cancer Treatment Vaccines
- (2010) V. Brower JNCI-Journal of the National Cancer Institute
- When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology
- (2010) Dan Greenberg et al. JNCI-Journal of the National Cancer Institute
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- New Therapies for Castration-Resistant Prostate Cancer
- (2010) Dan L. Longo NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
- (2010) R. A. Madan et al. ONCOLOGIST
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
- (2009) Mayer Fishman EXPERT OPINION ON BIOLOGICAL THERAPY
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mechanisms of T-cell inhibition: implications for cancer immunotherapy
- (2009) Elizabeth A Mittendorf et al. Expert Review of Vaccines
- Immunotherapy for Prostate Cancer: Walk, Don't Run
- (2009) Charles G. Drake JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
- (2008) Celestia S. Higano et al. CANCER
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
- (2008) C. T. Garnett et al. CLINICAL CANCER RESEARCH
- Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy
- (2008) R. A. Madan et al. CLINICAL CANCER RESEARCH
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- Peripherally Induced Treg: Mode, Stability, and Role in Specific Tolerance
- (2008) Irina Apostolou et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- (2008) Alessandro Testori et al. JOURNAL OF CLINICAL ONCOLOGY
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
- (2008) Christopher Wood et al. LANCET
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search